Lublin

• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 5 2023-12-11 ulcerative pyoderma gangrenosum
• Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease. Ended
  2024-512648-45-00 5 2023-11-30 Thyroid Eye Disease (TED)
• Study to investigate the efficacy of chaste tree (Vitex agnus-castus BNO 1095 (20 mg)) in women with cramping pain in the lower abdomen occu … Ended
  2023-503688-41-00 5 2023-11-28 Primary Dysmenorrhea
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25 Asthma
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended
  2022-503062-72-00 4 2023-11-23 Chronic Spontaneous Urticaria
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss. Ended
  2023-504421-39-00 5 2023-11-21 Androgenetic Alopecia
• A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended
  2022-502778-18-00 5 2023-11-17 ulcerative colitis
• Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLAN … Ended
  2023-505050-18-00 6 2023-11-16 Axial spondyloarthritis
• Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS) Ended
  2023-503915-14-00 4 2023-11-15 Primary Sjögren's Syndrome
• A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants … Ended
  2023-504338-24-00 5 2023-11-09 ESKD participants with history of secondary hyperparathyroidism (SHPT)
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr … Ended
  2023-504168-40-00 5 2023-11-06 Prevention of invasive extraintestinal pathogenic Escherichia coli (Ex
• A Phase 2 Safety and Immunogenicity Study of a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers Ended
  2023-505154-18-00 4 2023-11-02 Pneumococcal Infections
• A clinical trial to investigate efficacy and safety of NT 201 injections compared with placebo injections in participants aged 18 years and … Ended
  2022-501461-52-00 4 2023-10-17 Moderate to severe chronic peripheral neuropathic pain (PNP) due to po
• A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended
  2023-503657-35-00 5 2023-10-10 Obesity
• A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patient … Ended
  2024-511007-41-00 9 2023-10-03 Untreated advanced or metastatic non-squamous non-small cell lung canc
• BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended
  2024-514764-72-00 5 2023-09-27 Chronic Urticaria
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended
  2024-511615-16-00 4 2023-08-25 atopic dermatitis
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a

Showing 649–672 of 786 trials